← boardnext 2026-08-31next 2027-01
NRIX
Nurix Therapeutics, Inc.distress 6/10 · elevated risk$23.540%today-5% from 52w high
Oncology 2
Lead: Chronic Lymphocytic Leukemia (CLL) · target BTK · est. market ~$15B (approx, global)
Revenue
$15M
Liquidity
$294M
Runway
1.0 yrs
Shares 1y
+35%
Price & events
+21.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+2.0%
1W
+24.8%
1M
+42.0%
3M
+26.8%
6M
+102.4%
1Y
+4.1%
2Y
-23.4%
5Y
-27.7%
All
Overview
- Market Cap
- $2.44B
- Volume
- 94.48K
- 52 Week Range
- $8.24 – $24.69
- Total Shares
- 103.78M
- Float Shares
- 82.79M
- Short %
- 17.34%
- % Held by Insiders
- 1.08%
- % Held by Institutions
- 114.38%
- RVOL
- 0.04x
- Beta
- 1.80
Pipeline stages · 3 programs
NX-1607, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NX-5948, venetoclax, rituximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NX-2127
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-31 Estimated 50% readout ~2026-09-30 | Phase 1 | NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | recruiting |
| 2027-01 Estimated 50% readout ~2027-01-31 | Phase 1 | NX-5948fast track | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | NX-5948fast track | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | — | recruiting |
| 2029-10 Estimated 50% readout ~2029-12-15 | Phase 3 | NX-5948, Pirtobrutinibfast track | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | — | not yet recruiting |
| 2033-05 Estimated 50% readout ~2033-06-15 | Phase 1/2 | NX-5948, venetoclax, rituximabfast track | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | — | not yet recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-05 | Phase 1 | NX-2127 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL) | 248 | recruiting |
| 2026-04 | Phase 1 | NX-5948, Esomeprazolefast track | Healthy Volunteer | 18 | recruiting |
Catalyst news & presentations · 12
- 2026Guided 40%conferencedata presentationsecondaryBexobrutideg (NX-5948) · Presentation of new preclinical and Phase 1 translational data at the 2026 SID Annual Meeting.PR wire
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)bexobrutideg · Submit IND for tablet formulation in autoimmune indicationsSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3bexobrutideg · Initiate confirmatory Phase 3 trial DAYBreak CLL-306SEC 8-K
- 2026-10-08Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1/2bexobrutideg · Planned Phase 1b/2 combination study of bexobrutideg in CLL/SLL.SEC 8-K
- June 11–14, 2026 EHA Congressconferencedata presentationsecondaryPhase 1bexobrutideg (NX-5948) · Updated Phase 1a/b results presented at EHA2026SEC 8-K
- 2026-06-06partnershipbexobrutideg · License and Collaboration Agreement with Roche for $700M upfront and up to $2.3B in milestones, co-development/commercialization in US, Roche ex-US.SEC 8-K
- January 12, 2026conferencedata presentationsecondaryCorporate update at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- 2025trial initiationsecondaryPhase 3NX-5948 · Initiate pivotal studies in CLLSEC 8-K
- December 8, 2025conferencedata presentationsecondaryPhase 1bexobrutideg (NX-5948) · Presented Phase 1 data at ASH 2025SEC 8-K
- 2025-10-22trial initiationsecondaryPhase 2bexobrutideg · Initiated DAYBreak study, a pivotal single-arm Phase 2 trial of bexobrutideg in r/r CLL/SLL.SEC 8-K
- June 12, 2025conferencedata presentationsecondaryPhase 1bexobrutideg · Updated Phase 1 data presented at EHA2025SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $33 (+38% upside) · 16 analysts
- 2026-07-13MizuhoOutperform
- 2026-07-10RBC CapitalOutperform
- 2026-07-10StifelBuy
- 2026-07-10BTIGBuy
- 2026-07-10NeedhamBuy
- 2026-07-10HC Wainwright & Co.Buy
Competitors — BTK
- none identified
Recent news
- 2026-07-21Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - Investing News Network
- 2026-07-21Nurix to Receive $700M Upfront in Roche Bexobrutideg Deal - Stock Titan
- 2026-07-21Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - GlobeNewswire
- 2026-07-21Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
- 2026-07-20Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
- 2026-07-19How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue - webull.com
- 2026-07-18Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - MSN
- 2026-07-17Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.